2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study

BACKGROUND: Mold-active antifungal prophylaxis (ppx) is recommended in neutropenic patients with newly diagnosed AML or MDS. ISAV is an extended spectrum triazole with superior tolerability, reliability of absorption, fewer drug–drug interactions, lack of QT(c) prolongation or need for therapeutic d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Autores principales: Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Kadia, Tapan M, Borthakur, Gautam, Ravandi-Kashani, Farhad, Masarova, Lucia, Konopleva, Marina, Estrov, Zeev, Takahashi, Koichi, Yilmaz, Musa, Rausch, Caitlin R, Marx, Kayleigh, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811325/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1801
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares